SEVILLE, Spain, World Federation of Haemophilia Congress, May 21, 2002 -- Baxter BioScience today announced the launch of the BAXJECT needleless transfer device (BAXJECT), a safer, faster and easier way to prepare haemophilia medication without the use of sharp needles or fear of accidental injury. The BAXJECT device reduces the time it takes to prepare Factor VIII clotting therapy for infusion, allowing patients to more freely go about their lives.

"The BAXJECT device is convenient because it eliminates the handling or transfer of filter needles when preparing Factor VIII concentrates for infusion, said Bruce Ewenstein, M.D., global medical director for haemophilia therapy, Baxter BioScience. The whole process is safer and more streamlined, which goes a long way toward building confidence in anyone using the BAXJECT device to prepare haemophilia therapy. The device also is easy and safe enough for children to use, helping them to become more independent in managing their own condition.

Baxter acquired worldwide licensing rights for the use of the BAXJECT device in haemophilia patients in September 2001, a strategic move to further broaden the companys haemophilia franchise.

The BAXJECT device is compatible for use only with Baxter hemophilia therapies and will be introduced globally during the next six months. Initially the BAXJECT device will be available with Recombinate (recombinant antihaemophilic factor) and will eventually replace the transfer needles currently included in all packaging.

A RECOGNIZED NEED
The haemophilia community has asked for safer, faster and more convenient alternatives to preparing Factor VIII, a complicated process that is time-consuming and associated with the risk of needle-stick injury and contamination.

Needle-stick injury is an internationally recognized medical concern. The World Health Organization understands this and advocates that healthcare facilities develop standards, po
'"/>

Contact: Deborah Spak
847-948-2349
Porter Novelli
21-May-2002

Page: 1 2 3
Related medicine news :

1. FDA approves Baxters ADVATE for the treatment of hemophilia A
2. Applied Biosystems introduces next generation production level DNA analysis systems
3. Farnesyl transferase inhibitor can help patients at high-risk for developing AML
4. Rutgers-developed biomaterial drives a technology transfer story toward success
5. Painting technique successfully transfers gene therapy to heart
6. Rehabilitation professionals in nationwide survey cite barriers to assistive technology transfer
7. Delay in transfer to the ICU increases risk of death
8. Community hospitals do not transfer high-risk heart patients for aggressive therapy
9. Light-sensitive gloves reduce risk of germ transfer
10. Study shows low risk of vaccinia transfer after smallpox immunization
11. NIDA and SAMHSA agreement expedites transfer of research findings to clinical practice